Based on data collected from different sources by our team,
there are indicators that suggest that this company is no longer active. However, this information may not be accurate.
If you believe this information should be updated, please .
For more details, you can read our .
SIS Shulov Innovative Science
SIS Shulov Innovative Science Overview
Shulov Institute for Science (SIS) is an advanced clinical-stage biopharmaceutical company focusing on the development, manufacturing, and testing of novel pharmaceutical new chemical entities, based on natural compounds found in snake venom, towards clinical studies and commercialization.
The therapeutic targets for the current development are a wide range of dermatology indications including herpes (labialis, ocular, genital, and zoster), atopic dermatitis, psoriasis, and other skin disorders.
The leading compounds are short synthetic peptides (branded as ZEP-3 and ZEP-4), possessing unique biological activity and potent therapeutic use, including strong anti-viral, anti-inflammatory, and analgesic effects.
The company has completed an extensive chemistry, manufacturing, control package for the lead molecule API (ZEP-3) and is manufacturing under GMP in Israel and the United States.
SIS has completed a phase-II clinical study in herpes labialis (cold sores) with highly encouraging results in all end points, mainly time to healing, time to relief, and pain intensity.